Literature DB >> 36264416

IDO promotes the proliferation and invasion of prostate cancer cells through KYNU.

Hongqing Zhou1, Wei Wang1, Mingsheng Liu1, Pingbo Xie1, Tibin Deng1, Jiaxi Peng1, Chenxiang Xu2,3.   

Abstract

BACKGROUND: Prostate cancer (PCa) is one of the most common malignant tumors in male.
OBJECTIVE: To explore the effect of indoleamine-2, 3-dioxygenase (IDO) on the proliferation and invasion of PCa cells and the potential mechanism.
METHODS: PCa tissues and normal adjacent tissues were collected from 43 PCa patients. The expression of IDO in PCa tissues and cell lines were detected. The String website was used to search for IDO-related proteins. The GEPIA website was used to analyze the relationship between KYNU and the prognosis of PCa. Cells models of IDO overexpression and/or KYNU silencing were constructed to verify the role of KYNU in regulating PCa. The cell proliferation, apoptosis and invasion ability of PCa cells were detected by CCK-8 assay, Flow cytometry and Transwell assay.
RESULTS: The IDO levels in PCa tissues and cells were higher than those in normal tissues and cells, which promoted the proliferation and invasion of LNCaP cells, and inhibited apoptosis. Silencing IDO inhibited the cells proliferation and invasion activities, and promoted the cell apoptosis. The high expression of KYNU was related to the poor disease free survival of PCa patients. Inhibiting KYUN significantly inhibited the promotion of PCa induced by IDO.
CONCLUSION: IDO is overexpressed in PCa, which promotes the proliferation and invasion of PCa cells, and the cancer-promoting mechanism may be related to KYNU.
© 2022. The Author(s) under exclusive licence to The Genetics Society of Korea.

Entities:  

Keywords:  Indoleamine-2, 3-dioxygenase; Invasion; KYNU; Proliferation; Prostate cancer

Year:  2022        PMID: 36264416     DOI: 10.1007/s13258-022-01316-y

Source DB:  PubMed          Journal:  Genes Genomics        ISSN: 1976-9571            Impact factor:   2.164


  1 in total

1.  IDO inhibitor synergized with radiotherapy to delay tumor growth by reversing T cell exhaustion.

Authors:  Meng Liu; Ziyang Li; Weirong Yao; Xiaoping Zeng; Lingyun Wang; Jiao Cheng; Bingyu Ma; Ruiqian Zhang; Weiping Min; Hongmei Wang
Journal:  Mol Med Rep       Date:  2019-11-12       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.